Compile Data Set for Download or QSAR
Report error Found 149 Enz. Inhib. hit(s) with all data for entry = 7812
TargetReceptor tyrosine-protein kinase erbB-4(Human)
Pharmacyclics

US Patent
LigandPNGBDBM50357312(IBRUTINIB | US9181263, 1 | US9108973, Ref 1 | US92...)
Affinity DataIC50: 0.100nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetTyrosine-protein kinase Blk(Human)
Pharmacyclics

US Patent
LigandPNGBDBM97672(US8476284, 40 | US9133201, 10 | US9181263, 9 | US9...)
Affinity DataIC50: 0.200nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Pharmacyclics

US Patent
LigandPNGBDBM191606(US9181263, 23 | US9278100, 23 | US20240317756, Com...)
Affinity DataIC50: 0.320nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Pharmacyclics

US Patent
LigandPNGBDBM191605(US9181263, 14 | US9278100, 14 | US20240317756, Com...)
Affinity DataIC50: 0.390nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetTyrosine-protein kinase Fgr(Human)
Pharmacyclics

US Patent
LigandPNGBDBM97672(US8476284, 40 | US9133201, 10 | US9181263, 9 | US9...)
Affinity DataIC50: 0.400nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Pharmacyclics

US Patent
LigandPNGBDBM50357312(IBRUTINIB | US9181263, 1 | US9108973, Ref 1 | US92...)
Affinity DataIC50: 0.5nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor(Human)
Pharmacyclics

US Patent
LigandPNGBDBM50357312(IBRUTINIB | US9181263, 1 | US9108973, Ref 1 | US92...)
Affinity DataIC50: 0.5nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetTyrosine-protein kinase Blk(Human)
Pharmacyclics

US Patent
LigandPNGBDBM50357312(IBRUTINIB | US9181263, 1 | US9108973, Ref 1 | US92...)
Affinity DataIC50: 0.5nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Pharmacyclics

US Patent
LigandPNGBDBM50357312(IBRUTINIB | US9181263, 1 | US9108973, Ref 1 | US92...)
Affinity DataIC50: 0.5nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor(Human)
Pharmacyclics

US Patent
LigandPNGBDBM50357312(IBRUTINIB | US9181263, 1 | US9108973, Ref 1 | US92...)
Affinity DataIC50: 0.5nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Pharmacyclics

US Patent
LigandPNGBDBM191617(US9181263, 13 | US9278100, 13 | US20240317756, Com...)
Affinity DataIC50: 0.670nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetTyrosine-protein kinase Lck(Human)
Pharmacyclics

US Patent
LigandPNGBDBM220129(US9278100, 18 | US20240317756, Compound 18)
Affinity DataIC50: 0.760nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetCytoplasmic tyrosine-protein kinase BMX(Human)
Pharmacyclics

US Patent
LigandPNGBDBM50357312(IBRUTINIB | US9181263, 1 | US9108973, Ref 1 | US92...)
Affinity DataIC50: 0.800nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetTyrosine-protein kinase Yes(Human)
Pharmacyclics

US Patent
LigandPNGBDBM97672(US8476284, 40 | US9133201, 10 | US9181263, 9 | US9...)
Affinity DataIC50: 0.800nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetTyrosine-protein kinase Lck(Human)
Pharmacyclics

US Patent
LigandPNGBDBM191614(US9181263, 10 | US9278100, 10 | US20240317756, Com...)
Affinity DataIC50: 0.880nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Pharmacyclics

US Patent
LigandPNGBDBM191628(US9181263, 24 | US9278100, 24 | US20240317756, Com...)
Affinity DataIC50: 0.890nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Pharmacyclics

US Patent
LigandPNGBDBM220128(US9278100, 11)
Affinity DataIC50: 0.920nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Pharmacyclics

US Patent
LigandPNGBDBM97672(US8476284, 40 | US9133201, 10 | US9181263, 9 | US9...)
Affinity DataIC50: 1nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetTyrosine-protein kinase Lck(Human)
Pharmacyclics

US Patent
LigandPNGBDBM97672(US8476284, 40 | US9133201, 10 | US9181263, 9 | US9...)
Affinity DataIC50: 1nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetTyrosine-protein kinase HCK(Human)
Pharmacyclics

US Patent
LigandPNGBDBM97672(US8476284, 40 | US9133201, 10 | US9181263, 9 | US9...)
Affinity DataIC50: 1nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Pharmacyclics

US Patent
LigandPNGBDBM97672(US8476284, 40 | US9133201, 10 | US9181263, 9 | US9...)
Affinity DataIC50: 1nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetTyrosine-protein kinase Lck(Human)
Pharmacyclics

US Patent
LigandPNGBDBM97672(US8476284, 40 | US9133201, 10 | US9181263, 9 | US9...)
Affinity DataIC50: 1nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetCytoplasmic tyrosine-protein kinase BMX(Human)
Pharmacyclics

US Patent
LigandPNGBDBM97672(US8476284, 40 | US9133201, 10 | US9181263, 9 | US9...)
Affinity DataIC50: 1.10nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Pharmacyclics

US Patent
LigandPNGBDBM97675(BDBM698786 | US8497277, 15 | US9181263, 2 | US9278...)
Affinity DataIC50: 1.10nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetTyrosine-protein kinase Lyn(Human)
Pharmacyclics

US Patent
LigandPNGBDBM97672(US8476284, 40 | US9133201, 10 | US9181263, 9 | US9...)
Affinity DataIC50: 1.20nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Pharmacyclics

US Patent
LigandPNGBDBM191614(US9181263, 10 | US9278100, 10 | US20240317756, Com...)
Affinity DataIC50: 1.31nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Pharmacyclics

US Patent
LigandPNGBDBM191616(US9181263, 12 | US9278100, 12 | US20240317756, Com...)
Affinity DataIC50: 1.33nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Pharmacyclics

US Patent
LigandPNGBDBM220129(US9278100, 18 | US20240317756, Compound 18)
Affinity DataIC50: 1.38nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Pharmacyclics

US Patent
LigandPNGBDBM191613(US9181263, 8 | US9278100, 8)
Affinity DataIC50: 1.40nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetTyrosine-protein kinase Lck(Human)
Pharmacyclics

US Patent
LigandPNGBDBM191617(US9181263, 13 | US9278100, 13 | US20240317756, Com...)
Affinity DataIC50: 1.56nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Pharmacyclics

US Patent
LigandPNGBDBM191626(US9181263, 22 | US9278100, 22 | US20240317756, Com...)
Affinity DataIC50: 1.57nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Pharmacyclics

US Patent
LigandPNGBDBM191623(US9181263, 19 | US9278100, 19 | US20240317756, Com...)
Affinity DataIC50: 1.58nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetTyrosine-protein kinase Lck(Human)
Pharmacyclics

US Patent
LigandPNGBDBM50357312(IBRUTINIB | US9181263, 1 | US9108973, Ref 1 | US92...)
Affinity DataIC50: 2nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Pharmacyclics

US Patent
LigandPNGBDBM191621(US9181263, 17 | US9278100, 17 | US20240317756, Com...)
Affinity DataIC50: 2nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetTyrosine-protein kinase Lck(Human)
Pharmacyclics

US Patent
LigandPNGBDBM50357312(IBRUTINIB | US9181263, 1 | US9108973, Ref 1 | US92...)
Affinity DataIC50: 2nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetTyrosine-protein kinase Lck(Human)
Pharmacyclics

US Patent
LigandPNGBDBM191621(US9181263, 17 | US9278100, 17 | US20240317756, Com...)
Affinity DataIC50: 2.07nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetTyrosine-protein kinase CSK(Human)
Pharmacyclics

US Patent
LigandPNGBDBM50357312(IBRUTINIB | US9181263, 1 | US9108973, Ref 1 | US92...)
Affinity DataIC50: 2.20nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor(Human)
Pharmacyclics

US Patent
LigandPNGBDBM191605(US9181263, 14 | US9278100, 14 | US20240317756, Com...)
Affinity DataIC50: 2.30nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetTyrosine-protein kinase Fgr(Human)
Pharmacyclics

US Patent
LigandPNGBDBM50357312(IBRUTINIB | US9181263, 1 | US9108973, Ref 1 | US92...)
Affinity DataIC50: 2.30nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetTyrosine-protein kinase CSK(Human)
Pharmacyclics

US Patent
LigandPNGBDBM97672(US8476284, 40 | US9133201, 10 | US9181263, 9 | US9...)
Affinity DataIC50: 2.40nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetTyrosine-protein kinase Lck(Human)
Pharmacyclics

US Patent
LigandPNGBDBM220128(US9278100, 11)
Affinity DataIC50: 2.43nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetTyrosine-protein kinase Lck(Human)
Pharmacyclics

US Patent
LigandPNGBDBM191612(US9181263, 7 | US9278100, 7 | US20240317756, Compo...)
Affinity DataIC50: 2.60nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Pharmacyclics

US Patent
LigandPNGBDBM97678(US8497277, 10 | US8497277, 9 | US8476284, 9 | US91...)
Affinity DataIC50: 3.10nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Pharmacyclics

US Patent
LigandPNGBDBM191620(US9181263, 16 | US9278100, 16 | US20240317756, Com...)
Affinity DataIC50: 3.14nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetReceptor tyrosine-protein kinase erbB-4(Human)
Pharmacyclics

US Patent
LigandPNGBDBM97672(US8476284, 40 | US9133201, 10 | US9181263, 9 | US9...)
Affinity DataIC50: 3.20nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetProtein-tyrosine kinase 6(Human)
Pharmacyclics

US Patent
LigandPNGBDBM50357312(IBRUTINIB | US9181263, 1 | US9108973, Ref 1 | US92...)
Affinity DataIC50: 3.30nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetProtein-tyrosine kinase 6(Human)
Pharmacyclics

US Patent
LigandPNGBDBM97672(US8476284, 40 | US9133201, 10 | US9181263, 9 | US9...)
Affinity DataIC50: 3.30nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Pharmacyclics

US Patent
LigandPNGBDBM191629(US9181263, 25 | US9278100, 25 | US20240317756, Com...)
Affinity DataIC50: 3.48nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetTyrosine-protein kinase HCK(Human)
Pharmacyclics

US Patent
LigandPNGBDBM50357312(IBRUTINIB | US9181263, 1 | US9108973, Ref 1 | US92...)
Affinity DataIC50: 3.70nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetTyrosine-protein kinase Lck(Human)
Pharmacyclics

US Patent
LigandPNGBDBM191620(US9181263, 16 | US9278100, 16 | US20240317756, Com...)
Affinity DataIC50: 3.82nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

Displayed 1 to 50 (of 149 total ) | Next | Last >>
Jump to: